Literature DB >> 15781237

N-terminal helix reorients in recombinant C-fragment of Clostridium botulinum type B.

Seetharaman Jayaraman1, Subramaniam Eswaramoorthy, S Ashraf Ahmed, Leonard A Smith, Subramanyam Swaminathan.   

Abstract

Botulinum neurotoxins comprise seven distinct serotypes (A-G) produced by Clostridium botulinum. The crystal structure of the binding domain of the botulinum neurotoxin type B (BBHc) has been determined to 2A resolution. The overall structure of BBHc is well ordered and similar to that of the binding domain of the holotoxin. However, significant structural changes occur at what would be the interface of translocation and binding domains of the holotoxin. The loop 911-924 shows a maximum displacement of 14.8A at the farthest point. The N-terminal helix reorients and moves by 19.5A from its original position. BBHc is compared with the binding domain of the holotoxin of botulinum type A and B, and the tetanus C-fragment to characterize the heavy chain-carbohydrate interactions. The probable reasons for different binding affinity of botulinum and tetanus toxins are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781237     DOI: 10.1016/j.bbrc.2005.02.123

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

2.  Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding.

Authors:  Pål Stenmark; Min Dong; Jérôme Dupuy; Edwin R Chapman; Raymond C Stevens
Journal:  J Mol Biol       Date:  2010-02-26       Impact factor: 5.469

3.  Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction.

Authors:  Pål Stenmark; Jérôme Dupuy; Akihiro Imamura; Makoto Kiso; Raymond C Stevens
Journal:  PLoS Pathog       Date:  2008-08-15       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.